Subacute liver failure induced by adalimumab

International Journal of Clinical Pharmacology and Therapeutics

Volumn 49, Issue 1, 2011, Pages 38-40

  Hagel, S ^a   Bruns, T ^a   Theis, B ^a   Herrmann, A ^a   Stallmach, A ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Adalimumab; Adverse reactions; Hepatitis; Liver failure; Psoriatic arthritis

Indexed keywords

ADALIMUMAB; METHOTREXATE; PREDNISOLONE;

ADULT; AMMONIA BLOOD LEVEL; ARTICLE; BLOOD ANALYSIS; CASE REPORT; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATOMEGALY; HUMAN; HUMAN TISSUE; INTERNATIONAL NORMALIZED RATIO; INTRAHEPATIC CHOLESTASIS; JAUNDICE; LIVER BIOPSY; LIVER FAILURE; LIVER FUNCTION TEST; LIVER METABOLISM; LIVER NECROSIS; LIVER TOXICITY; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PSORIATIC ARTHRITIS; SIDE EFFECT; SUBACUTE LIVER FAILURE; TOXIC HEPATITIS;

ACUTE DISEASE; ADULT; ALANINE TRANSAMINASE; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; LIVER FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78650807484     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP49038     Document Type: Article

References (12)

1. Traczewski P, Rudnicka L. Adalimumab in dermatology. Br J Clin Pharmacol. 2008; 66: 618-625.
2. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008; 117: 244-279.
3. Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, Donovan C. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis. 2006; 65: 889-894.
4. Dominique L. Liver toxicity of TNFalpha antagonists. Joint Bone Spine. 2008; 75: 636-638.
5. Davern TJ. Hepatotoxicity of immunomodulating agents and the transplant situation. In: Kaplowitz N, DeLeve LD (eds). Drug-induced liver disease. 2nd. edition. New York: Informa Healthcare; 2007. p. 662-681.
6. Farah M, Al RA, Owen DA, Yoshida EM, Reid GD. Granulomatous hepatitis associated with etanercept therapy. J Rheumatol. 2008; 35: 349-351. (Pubitemid 351281159)
7. FDA Briefing document. Arthritis Advisory committee. Available at: http://www.fda.gov/ohrms/dockets/ac/03/transcripts/3930T1.htm. Accessed August 3, 2009.
8. Leak AM, Rincon-Aznar B. Hepatotoxicity associated with etanercept in psoriatic arthritis. J Rheumatol. 2008; 35: 2286-2287.
9. Thiefin G, Morelet A, Heurgue A, Diebold MD, Eschard JP. Infliximab-induced hepatitis: absence of cross-toxicity with etanercept. Joint Bone Spine. 2008; 75: 737-739.
10. FDA Remicade label. Available at: http://www.accessdata.fda.gov/ drugsatfda-ocs/label/2009/103772s5234lbl.pdf. Accessed August 3, 2009.
11. FDA Humira label. Available at: http://www.accessdata.fda.gov/drugsatfda- ocs/label/2008/125057s114lbl.pdf. Accessed August 3,2009.
12. Mease PJ, Ory P, Sharp JT, Ritchlin CT, van den Bosch F, Wellborne F, Birbara C, Thomson GTD, Perdok RJ, Medich J, Wong RL, Gladman DD. Adalimumab for long-term treatment of psoriatic arthritis: two-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis. 2009; 68: 702-709.